Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPPA: Capecitabine + Pembrolizumab in TNBC
NCT05973864Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Mar 2025
- Primary completion
- Aug 2028
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in triple-negative breast cancer (TNBC), sponsored by Unicancer. Started Mar 2025; status: recruiting.
02
Drugs
capecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05973864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05973864.